Kornimate/medical-research-clean huggingface dataset:
the mechanical characterisation of human saphenous and popliteal vein

Conditions: Peripheral Vascular Diseases

Summary: non-interventional study aiming to ascertain the mechanical properties of human saphenous and popliteal vein tissue.

the aim of this study is to mechanically characterise saphenous and popliteal vein segments that have been deemed waste following varicose vein procedures, lower limb amputation and lower limb bypass surgery. by characterising the stress-stretch relationship of the vein vessel wall, treatment techniques can be better understood. mechanical device design can be bteer informed and the the suitability of vein as a conduit for bypass and avf procedures can be assessed.

Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or older * patients undergoing varicose vein procedures or; * patients undergoing lower limb amputation or; * patients undergoing lower limb bypass surgery exclusion criteria: * patients unable to give informed consent * seriously ill/unconscious patients
altering activation patterns post-stroke

Conditions: Stroke; Muscle Spasticity; Hemiparesis

Summary: this study evaluates a new rehabilitation approach for stroke survivors in the chronic phase of recovery in which the combination of drug therapy (cyproheptadine) and active movement practice (amp) is used to encourage increased voluntary muscle control and strength.

in this four arm parallel design you will be randomly assigned to one of 4 groups: group 1) cyproheptadine and active movement therapy, group 2) placebo and active movement therapy, group 3) cyproheptadine and passive stretching, or group 4) placebo and passive stretching. the groups will be blinded so neither you nor the research staff (or even the study doctor) will know which drug (cyproheptadine or placebo) you receive. only the ric pharmacist will have access to this information until all participants complete the entire study. although you and the research staff administering the training sessions will know if you have been assigned to the active movement practice (amp) or passive cyclical stretching group, it is important not to discuss this information with the rater (evaluator) or the study doctor. cyproheptadine is an anti-serotonergic and anti spastic agent. it is expected to reduce the unwanted muscle hyper excitability (one measure of spasticity) common after stroke. during the course of the treatment you will be required to make several visits per week to ric to either be evaluated or participate in the treatment sessions. evaluations last approximately 2 hours and will be performed at the beginning of weeks 1, 2, 3 and 4, during the middle of treatment (beginning of week 7), at the end of training (beginning of week 10) as well as a final follow-up visit one month after the end of treatment (beginning of week 14). the training sessions will occur from weeks 4 through week 9 and will involve 1.5-hr. sessions (1 hr training plus setup time) 3 times per week. the investigators hypothesize that the group receiving the combined cyproheptadine and active movement therapy will have better outcomes than the groups receiving cyproheptadine or active movement therapy alone.

Eligibility criteria:
inclusion criteria: * chronic, severe hand hemiparesis resulting from a single stroke (chedoke- mcmaster stroke assessment: stage of hand 2 or 3) * single stroke occurring at least 6 months prior to enrollment * spasticity * capacity to provide informed consent exclusion criteria: * excessive pain in paretic upper limb * hemispatial neglect (as assessed by the behavioral inattention test) * apraxia (as assessed by the fabers battery) * botulinum toxin injection in the upper extremity within the past 6 months * introduction of new anti-spasticity medication within the past 6 months * orthopaedic impairments * history of seizure disorder * other major health impairment

Keywords: hand rehabilitation active movement training passive cyclical stretching
expanded nipt for pregnancy complications

Conditions: Fetal Growth Restriction; Preeclampsia Severe

Summary: this study evaluates the utility of expanded panel non-invasive prenatal testing (nipt) in detecting confined placental mosaicism of rare autosomal trisomies among pregnancies with placentally-mediated complications, including fetal growth restriction and severe preeclampsia.


Eligibility criteria:
inclusion criteria: * diagnosis of early onset (\< 34 weeks) severe fetal growth restriction, defined as estimated fetal weight less than 10th percentile with abnormal umbilical artery dopplers or estimated fetal weight less than 5th percentile alone or biometric size at least 14 days behind expected dates exclusion criteria: * maternal age \< 18 years * multifetal gestation * chronic hypertension require use of pharmacotherapy * tobacco or drug use * major congenital malformations
continuous versus bolus administration of norepinephrine to treat hypotension during anesthetic induction

Conditions: Intraoperative Hypotension

Summary: intraoperative hypotension is common in patients having non-cardiac surgery with general anesthesia and is associated with organ injury and death. the timely treatment of intraoperative hypotension is thus important to avoid postoperative complications. about one third of intraoperative hypotension occurs during anesthetic induction - i.e., between the start of anesthetic induction and surgical incision. hypotension during anesthetic induction is associated with postoperative acute kidney injury. unmodifiable risk factors for hypotension during anesthetic induction include age, male sex, and a high american society of anesthesiologists physical status class. however, hypotension during anesthetic induction is mainly driven by modifiable factors - specifically, anesthetic drugs that cause vasodilation. in most german hospitals, norepinephrine is the first-line vasopressor to treat hypotension during anesthetic induction. norepinephrine is usually given as repeated manual boluses of 5, 10, or 20 μg. the continuous administration of norepinephrine via a perfusion pump is usually started only later. it remains unknown whether giving norepinephrine continuously - compared to giving it as repeated manual boluses - reduces hypotension during anesthetic induction. we thus propose to investigate whether giving norepinephrine continuously - compared to giving it as repeated manual boluses - reduces hypotension during anesthetic induction in non-cardiac surgery patients.


Eligibility criteria:
inclusion criteria: * non-cardiac surgery * \>45 years of age * american society of anesthesiologists physical status classification ii, iii, and iv. exclusion criteria: * planned intraarterial blood pressure monitoring during anesthetic induction with an arterial catheter * emergency surgery * transplant surgery * history of organ transplant * pregnancy * heart rhythms other than sinus rhythm * impossible finger-cuff blood pressure monitoring * rapid sequence induction
effects of supplementation of compound nutrients on plasma homocysteine in chinese adults with hyperhomocysteinemia

Conditions: Hyperhomocysteinemia

Summary: the purpose of this study is to determine whether supplementation of compound nutrients,including folic acid, vitamin b6, vitamin b12, betaine and zinc, will decrease the level of plasma homocysteine in chinese adults with hyperhomocysteinemia.


Eligibility criteria:
inclusion criteria: 1. people aged 18-65 years. 2. the level of plasma homocysteine is 15-100μmol/l. 3. free from products which could decrease plasma homocysteine for at least one month. 4. willing to participate in the study, consume the test product and perform all measurements. exclusion criteria: 1. pregnant or lactating women. 2. severe diseases need to control. 3. people who unconsciousness and can not complete questionnaire. 4. long-term regular use of vitamin or mineral supplements.
microdialysis and jugular bulb glucose profiles during hyperglycaemic clamping in patients with severe acute brain injury

Conditions: Acute Brain Injury

Summary: acute brain injury is a serious condition that often results in admission to an intensive care unit. some of the most seriously ill patients are fitted with multimodal neuromonitoring, a newer monitoring modality that can, among other things, measure oxygen tension and sugar levels in brain tissue. it is common clinical practice, but the interaction between the body's sugar levels and the brain's sugar levels is not sufficiently elucidated. the study will investigate the relationship between the body's sugar levels, measured in arterial and venous blood, and the brain's sugar level, measured by microdialysis, in patients with severe acute brain injury. furthermore, we hope to be able to use our measurements to set up a mathematical model for the brain's sugar uptake.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * admission to the neuro-icu at rigshospitalet. * multimodal neuromonitoring exclusion criteria: * closest relative does not understand written and spoken danish or english. * patients with known diabetes mellitus upon admission.

Keywords: acute brain injury intensive care neurointensive care anaesthesiology multimodal neuromonitoring glucose hyperglycaemic clamp
matching cognitive remediation to cognitive deficits in substance-abusing inmates

Conditions: Psychopathy; Personality Disorders

Summary: this is a 2 -year nida funded grant (co-pis: joseph p. newman, john curtin, and carl lejuez) that examines whether recent progress in characterizing the cognitive deficits associated with psychopathic and externalizing offenders may be used to develop better therapeutic interventions to treat their substance abuse and other self-control problems. inmates with externalizing or psychopathy will receive one of two computer-based interventions to remediate the core cognitive skills that have been linked to self-regulation deficits in the two groups. one intervention (acc) targets the affective cognitive control deficits associated with externalizing offenders whereas the other intervention (atc) targets the attention to context deficits associated with psychopathic offenders. the specific components of the project include: selection and randomization of inmates; pre- and post-treatment behavioral and brain-related (erp and startle) measures to evaluate the impact and specificity of the acc and atc treatments; and 6 sessions of behavioral (e.g. computerized) and verbal training in acc or atc.


Eligibility criteria:
inclusion criteria: * male, * ages 18-45 years, * elevated scores of psychopathy or externalizing measures exclusion criteria: * currently taking psychotropic medication, * below a 4th grade reading level, * history or current learning disability, * history of head trauma with lasting effects, * current diagnosis of ptsd, * bipolar, or * psychosis

Keywords: incarcerated offenders emotionally reactive emotionally stable psychopathy
ig nextgen 10% in idiopathic thrombocytopenic purpura (itp) patients

Conditions: Idiopathic Thrombocytopenic Purpura (ITP)

Summary: idiopathic thrombocytopenic purpura (itp) is an autoimmune bleeding disorder characterised by isolated low platelet counts. the aim of treating patients with itp is to increase the platelet concentration and reduce the risk of bleeding. a number of controlled multi-centre studies have demonstrated that intravenous immunoglobulin (ivig) therapy produces a rapid rise in platelet counts within a 24 to 72 hour period. this study will evaluate the efficacy and safety of ig nextgen 10% in adult patients with itp.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of itp * platelet count of \<50 x 10\^9 exclusion criteria: * planned splenectomy * previous non-responders to ivig treatment * known or suspected hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy * patients who have received treatment with: 1. ivig or anti-d immunoglobulin 2. immunosuppressive, any other immunomodulatory drug(s) or other active treatment(s)for itp within three weeks prior to first day of study drug administration 3. patients who have received iv administration of steroids or have had a change of oral corticosteroid treatment or danazol within 15 days prior to first day of study drug administration.

Keywords: itp ivig platelet count bleeding
stem cell therapy in patients with myocardial infarction and persistent total occlusion of infarct related artery

Conditions: Acute Myocardial Infarction

Summary: background: when an acute myocardial infarction occurs, the artery supplying the infarct zone should be opened within twenty four hours of onset of infarction. this has clearly been shown to be beneficial. if the patient presents later than 24 hours of onset, at that stage a large part of the damage to the heart is irreversible. intervening at this stage (beyond 24 hours is controversial). some trials suggest that opening the artery even at this stage positively modifies the remodeling process while other trials suggest that such a benefit is not seen. hypothesis: opening an infarct related artery after 24 hours (until 6 months) and combining it with intracoronary stem cell therapy may provide incremental benefit.it is possible that the lack of benefit seen with late revascularization (\>24 hrs) after mi may be offset by giving intracoronary stem cells after opening the artery.

objectives the benefit of opening an infarct related artery after the period of myocardial salvage (in patients who do not come to medical attention within 24 hrs of an infarctions) has been questioned in recent trials. on the other hand, stem cell therapy after myocardial infarction has been shown to improve myocardial function both in the acute and chronic phases. it is possible that the lack of benefit seen with late revascularization (\>24 hrs) after mi may be offset by giving intracoronary stem cells after opening the artery. patients with recent myocardial infarction (mi) and occluded infarct related arteries supplying a large myocardial territory and with reduced ejection fraction will be randomized to a percutaneous coronary intervention (pci) arm and a pci plus stem cell arm . the objective of the trial is to demonstrate that opening an infarct related artery after 24 hours and before six months and following it with intracoronary stem cell therapy may provide incremental benefit. the primary objective to demonstrate benefits in left ventricular recovery (improvement in function by echocardiogram and nuclear imaging: multigated acquisition \[muga\], reduction in scar size by tetrofosmin scan/positron emission tomography\[pet\]. ) the secondary objectives to demonstrate improvement in functional capacity as assessed by 6 minute walk test and quality of life assessment, along with reduction of first occurrence of recurrent mi, hospitalization/treatment of new york heart association class iv congestive heart failure, or death

Eligibility criteria:
inclusion criteria: 1. age:18 to 80 years 2. sex:both 3. recent mi (3-28 d) 4. obstructed artery needing intervention 5. consent for stem cell therapy exclusion criteria: 1. left main disease or triple vessel disease\[tvd\] needing surgery 2. hypotension 3. consent not given

Keywords: myocardial infarction
a comparative study of global 12 lead electroencephalogram to frontal sedlinetm electroencephalogram

Conditions: Craniotomy; Transphenoidal Pituitary Resection

Summary: the fundamental reason for comparing the ability of the frontal sedline tm electroencephalogram (psa eeg) to standard global 12 lead electroencephalogram (eeg) for burst suppression detection is to determine if a less expensive, less invasive and possibly more convenient bifrontal eeg monitor can be effective for evaluation of anesthesia-induced intraoperative burst suppression therapy (ibst) for cerebral protection.


Eligibility criteria:
inclusion criteria: 1. adult asa class 1-3 male or female 18-90 years of age; 2. scheduled for elective craniotomy in the llumc university hospital, for which the surgeon has requested intraoperative burst suppression therapy; 3. capable of understanding and signing informed consent; 4. willing to have dual eeg monitoring. exclusion criteria: 1. age under 18 years; 2. emergency or trauma situation requiring craniotomy; 3. surgical approach that prohibits placing the sedlinetm array on the forehead; 4. known sensitivity to the adhesives on the sedlinetm array; 5. lack of availability of standard eeg monitoring; 6. patients with seizure disorders and refusal of consent.
evaluation of the efficacy of vertistop® d and vertistop® l in the prevention of bppv recurrence

Conditions: Benign Paroxysmal Positional Vertigo; Vitamin D; Antioxidants

Summary: the study involves the evaluation of 3 groups of subjects (3-arm study). patients diagnosed with bppv and "sufficient" serum concentrations of vitamin d (\>30 ng/ml, \>75 nmol/l) at baseline may be treated with 2 tablets per day (morning and evening) of vertistop® l ( alpha-lipoic acid, carnosine, zinc and curcumin) or untreated, on the basis of the randomization criterion to which they will be assigned. patients with vitamin d "deficiency" (\<20 ng/ml, \<50 nmol/l) or vitamin d "insufficient" (20-30 ng/ml, 50-75 nmol/l) at baseline, or subsequent follow-up, they will be treated for 2 months with vertistop® d (alpha-lipoic acid, carnosine and zinc, vitamin d3 and vitamins of the b complex) taking 1 tablet a day (before meals). the main purpose of the study is to evaluate, over a period of 6 months, the efficacy of vertistop® d and vertistop® l supplementation in preventing recurrences of bppv (benign paroxysmal positional vertigo), in relation to blood levels of vitamin d.

patients will be assigned to one of the three study groups following a randomization list with reference to groups 1 and 2 and according to the serum concentrations of 25(oh) vitamin d, evaluated at the baseline visit, with reference to group 3. the determination of the vitamin d concentration will be requested by the investigating physician and the report will be evaluated during the randomisation visit (v1), visit 2, (after 2 months from enrollment/start of treatment), visit 3 (follow-up visit up to 4 months from enrollment) and finally visit 4 (follow-up visit 6 months after enrollment). the blood sample and the vitamin d dosage will be carried out the week before the day of the visit agreed with the investigator, in a trusted laboratory of the patient, provided that it has the legal authorizations and the analytical methodology satisfactory the measurement intervals reported in protocol.

Eligibility criteria:
inclusion criteria: 1. patients of both sexes, aged between 18 and 85 years, diagnosed with primary bppv. 2. patients who have bppv of the posterior semicircular canal (spc) geo and apo, lateral semicircular canal (slc) geo and apo (single-canal, multi-canal). 3. patients with relapsing bppv, defined as two or more episodes in the past six months, or three or more episodes in the last 12 months. 4. patients able to understand and follow the requirements of the study protocol and to provide their informed consent. exclusion criteria: 1. patients under the age of 18. 2. secondary bppv. other causes of possible high recurrence bppv and/or massive otolithic detachment: * migraine; * meniere's or delayed endolymphatic hydrops; * lindsay hemenway syndrome; * otological and/or dental implant surgery in the last 3 months; * conclusion within 30 days. 3. patients with vitamin d values exceeding 100 ng/ml (\>250 nmol/l). 4. pregnant or lactating women, as reported by the patient.
iressa as second line therapy in advanced nsclc-asia

Conditions: NSCLC

Summary: this is a randomized, open-label, parallel group, phase iii, multicenter, regional study. the total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational sites throughout the asia pacific region that have expertise in treating patients with nsclc.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed non-small cell bronchogenic carcinoma: adenocarcinoma (including bronchoalveolar), squamous cell carcinoma, large cell carcinoma or mixed (adenocarcinoma and squamous) or undifferentiated carcinoma. * who performance status 0-2 * nsclc - locally advanced (stage iiib) or metastatic (stage iv) disease, not amenable to curative surgery or radiotherapy * life expectancy of 12 weeks. exclusion criteria: * alt/ast: \>2.5x ulrr if no demonstrable liver metastases or greater than 5 x ulrr in the presence of liver. * inadequate bone marrow function; absolute neutrophil count: \<1.5 x 109/l, platelets: \< 100 x 109/l * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma of skin or cervical cancer in situ

Keywords: non-small cell lung cancer
ketone supplementation, glucose control, and cardiovascular function

Conditions: Hyperglycemia, Postprandial; Overweight and Obesity; Diabetes Mellitus Risk

Summary: post-prandial hyperglycemic excursions induce a cascade of deleterious effects on the body, including increased inflammation, production of reactive oxygen species, and impaired cardiovascular function. ingestion of an exogenous oral ketone supplement blunts hyperglycemia in response to an oral glucose tolerance test. accordingly, it is hypothesized that exogenous ketone supplement ingestion prior to a meal could be an effective strategy for blunting postprandial hyperglycemia. therefore, the purpose of this study is to investigate the effect of short-term (14-days) pre-meal exogenous ketone supplementation on glucose control, cardiovascular function, inflammation, and oxidative stress in individuals at an elevated risk of type 2 diabetes.


Eligibility criteria:
inclusion criteria: * elevated waist circumference (\>102 cm for males, \>88 cm for females) and/or obesity (bmi \> 30 kg/m2) and/or diagnoses of prediabetes based on a1c (5.7-6.4%) and/or fasting plasma glucose (5.6-6.9 mmol/l) using ada criteria exclusion criteria: * competitively trained endurance athlete * actively attempting to lose weight * history of mental illness or existing neurological disease(s) * previous cardiovascular events (i.e., heart attack, stroke) * diagnoses of diabetes * hypoglycemia * irritable bowel syndrome or inflammatory bowel disease * taking medication that may interfere with insulin sensitivity * currently following a ketogenic diet or taking ketone supplements * unable to commit for 2 separate 14-day trials and unable to follow a controlled diet

Keywords: flow mediated dilation glucose control inflammation immune cell function cognition oxidative stress cardiovascular function
study of the natural history and genotype-phenotype correlations of hereditary hemorrhagic telangiectasia patients

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: objectives: i. collect data regarding the natural history of hereditary hemorrhagic telangiectasia (hht). ii. establish genotype-phenotype correlations in hht. iii. create a database of information for researchers throughout the world.

protocol outline: patients complete a self-administered natural history questionnaire in a multiple choice format. questionnaire is completed by a population consisting of males and females of all ages and ethnic backgrounds. data are collected and made available to all researchers.

Eligibility criteria:
* diagnosed hereditary hemorrhagic telangiectasia (osler-rendu-weber disease) with recurrent epistaxis, telangiectases, and visceral vascular anomalies

Keywords: genetic diseases and dysmorphic syndromes hematologic disorders hereditary hemorrhagic telangiectasia rare disease